Know Cancer

forgot password

Neoadjuvant Anti-CTLA4 Blockade With Ipilimumab in Patients With AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis

18 Years
Open (Enrolling)

Thank you

Trial Information

Neoadjuvant Anti-CTLA4 Blockade With Ipilimumab in Patients With AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis

Inclusion Criteria:

- Willing and able to give written informed consent.

- Histologic diagnosis of melanoma belonging to T1-4 N1b,2b,2c,3 M 0 AJCC stages, that
may present as any of the following groups:

- Primary melanoma with clinically apparent (overt) regional lymph node metastases,
confirmed by pathological diagnosis (biopsy).

- Clinically detected recurrence of melanoma at the proximal regional lymph node(s)
basin, confirmed by pathological diagnosis (biopsy).

- Clinically or histologically detected primary melanoma involving multiple regional
nodal groups, confirmed by pathological diagnosis (biopsy).

- Clinically detected single site of nodal metastatic melanoma arising from an unknown
primary, confirmed by pathological diagnosis (biopsy).

- Patients are eligible for this trial either at presentation for primary melanoma with
concurrent regional nodal metastasis, or at the time of clinically detected nodal
recurrence. Patients must undergo biopsy (punch) or open biopsy (if done as part of a
clinically indicated baseline diagnostic procedure) within 14 days of entry into the
study. Lymphadenectomy will be performed after at least 2 and generally not longer
than 4 weeks of ipilimumab therapy. Additional delays for definitive lymphadenectomy
are allowed if clinically indicated while awaiting the resolution of potential
adverse events from ipilimumab therapy.

- Patients must have been evaluated by standard-of-care full body imaging studies (CT,
PET-CT or MRI) as part of the initial clinical work-up at baseline (no more than 4
weeks prior to study enrollment) and after completion of 2 doses of ipilimumab (at
6-8 weeks after the first dose of ipilimumab and prior the definitive lymphadenectomy

- Required values for initial laboratory tests:

- WBC ≥ 3000/uL

- ANC ≥ 1500/uL

- Platelets ≥ 100 x 103/uL

- Hemoglobin ≥ 10 g/dL

- Creatinine ≤ ULN

- AST/ALT ≤ 2.5 x ULN

- Bilirubin ≤ ULN, (except patients with Gilbert's Syndrome, who must have a total
bilirubin less than 3.0 mg/dL)

- PT/PTT ≤ ULN (No active or chronic infection with HIV, Hepatitis B, or Hepatitis

- Adequate performance status (ECOG 0, 1).

- Men and women, ≥ 18 years of age.

- Women of childbearing potential (WOCBP) must be willing to use an adequate method of
contraception to avoid pregnancy throughout the study and for up to 8 weeks after the
last dose of ipilimumab. WOCBP include any female who has experienced menarche and
who has not undergone a successful surgical sterilization procedure (hysterectomy,
bilateral tubal ligation, or bilateral oophorectomy) or is not post-menopausal.
Post-menopause is defined as:

- Amenorrhea ≥ 12 consecutive months without another cause, or

- For women with irregular menstrual periods and taking hormone replacement
therapy (HRT), a documented serum follicle stimulating hormone (FSH) level ≥ 35

- Women who are using oral contraceptives, other hormonal contraceptives (vaginal
products, skin patches, or implanted or injectable products), or mechanical products
such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides)
to prevent pregnancy, or are practicing abstinence or where their partner is sterile
(eg, vasectomy) should be considered to be of childbearing potential. WOCBP must have
a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent
units of HCG) within 72 hours before the start of ipilimumab.

Exclusion Criteria:

- Patients with clinical, radiological/laboratory, or pathological evidence of distant
metastatic disease.

- Patients with evidence of soft tissue involvement by gross extranodal extension of
tumor manifest by fixation to the fascia, or matting of nodal tissue that would
compromise surgical resection as determined by the surgical oncologist.

- Patients who have had a history of acute diverticulitis, intra-abdominal abscess, GI
obstruction and abdominal carcinomatosis which are known risk factors for bowel

- Any other malignancy from which the patient has been disease-free for less than 5
years, with the exception of adequately treated and cured basal or squamous cell skin
cancer, superficial bladder cancer or carcinoma in situ of the cervix.

- Autoimmune disease: Patients with a history of inflammatory bowel disease are
excluded from this study, as are patients with a history of symptomatic disease (eg,
rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus
erythematosus, autoimmune vasculitis [eg, Wegener's Granulomatosis]); motor
neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome).

- Any underlying medical or psychiatric condition, which in the opinion of the
investigator will make the administration of ipilimumab hazardous or obscure the
interpretation of AEs, such as a condition associated with frequent diarrhea.

- Patients with underlying heart conditions who are deemed ineligible for surgery by
cardiology consult.

- Any non-oncology vaccine therapy used for prevention of infectious diseases (for up
to 1 month before or after any dose of ipilimumab).

- A history of prior treatment with ipilimumab or prior CD137 agonist or CTLA-4
inhibitor or agonist.

- A history of prior radiotherapy, chemotherapy, including infusion or perfusion
therapy for his current disease or any immunotherapy including tumor vaccines,
interferon-alfa, interleukins, levamisole or other biologic response modifiers within
the past 4 weeks.

- Concomitant therapy with any of the following: IL 2, interferon, or other non-study
immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other
investigation therapies; or chronic use of systemic corticosteroids; unless
discontinued ≥ 4 weeks.

- Women of childbearing potential (WOCBP), defined above in Section 4.1, who:

- are unwilling or unable to use an acceptable method of contraception to avoid
pregnancy for their entire study period and for at least 8 weeks after cessation of
study drug, or

- have a positive pregnancy test at baseline, or

- are pregnant or breastfeeding.

- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
treatment of either a psychiatric or physical (eg, infectious) illness.

Before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy
during study participation and the potential risk factors for an unintentional pregnancy.
All WOCBP MUST have a negative pregnancy test before first receiving ipilimumab. If the
pregnancy test is positive, the patient must not receive ipilimumab and must not be
enrolled in the study.

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To study the effects of ipilimumab upon the host immune response in nodal metastatic melanoma and in the peripheral blood comparing pre-treatment with post-treatment (baseline, 6 weeks) immunologic features.

Outcome Time Frame:

2.5 years

Safety Issue:


Principal Investigator

Ahmad Tarhini, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

December 2009

Completion Date:

September 2013

Related Keywords:

  • Melanoma
  • Immunogenicity Analysis
  • Biomarker Analysis
  • experimental
  • Melanoma



University of Pittsburgh Medical Center/University of Pittsburgh Cancer InstitutePittsburgh, Pennsylvania  15213